Laqunimod compared to placebo in patients with Relapsing -Remitting Multiple
Sclerosis (RRMS)
Trial Status
Open for Enrollment
What is the Purpose of this Study?
To assess the efficacy, safety and tolerability of laquinimod over placebo
and a reference arm of AVONEX.
Who is Eligible to Participate?
Patients 18-55 years of age diagnosed with MS who have had 1 relapse in
12 months prior to screening and who do not meet any exclusionary criteria
which will be addressed in further detail by study coordinator.
What is involved in this Study?
Eligible patients will be randomized in a 1:1:1 ratio. Group 1 will receive
.6 mg of Laquinimod once daily. Group 2 will receive placebo once daily.
Group 3 will receive AVONEX 30 mcg intramuscular injection once weekly.
How long is the Study?
The study will be 25 months long. Treatment phase will be 24 months of
once daily oral administration or once-weekly intramuscular administration
of AVONEX.
For More Information Contact: Lynne E. Flynn, CCRC, study coordinator, at
602-258-2863 or lynneflynn@pnal.net or call the Main line at 602-258-3354
|
